Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Linoleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 4/20 | 0.57 |
| ▸ | MAOA | P21397 | 4/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | F7 | P08709 | 4/20 | 0.49 |
| ▸ | F3 | P13726 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleic Acid SCHEMBL933220 | 0.98 | MAOA (0.59) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL933851 | 0.92 | ACHE (0.67) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL934461 | 0.92 | ACHE (0.67) | MAOAMAOBACHEBCHEADRA2B | |
| Palmitic Acid SCHEMBL2028967 | 0.92 | ACHE (0.67) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL932880 | 0.91 | ACHE (0.68) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL1818820 | 0.85 | ACHE (0.75) | MAOAMAOBACHEBCHEADRA2B | |
| Rasagiline SCHEMBL1820428 | 0.82 | ACHE (0.79) | MAOAMAOBACHEBCHEADRA2B | |
| SCHEMBL11442873 | 0.81 | CA12 (0.56) | ALDH1A1HPGDMEN1MAPTKMT2A | |
| SCHEMBL11442872 | 0.81 | CA12 (0.56) | ALDH1A1HPGDMEN1MAPTKMT2A | |
| Rasagiline SCHEMBL933178 | 0.80 | ACHE (0.79) | MAOAMAOBACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946482-B2 | Salts of rasagiline and pharmaceutical preparations thereof | RATIOPHARM GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2451771-B1 | SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF | RATIOPHARM GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-20120142966-A1 | SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF | RATIOPHARM GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-2451771-A1 | SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF | Ratiopharm GmbH (DE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011003938-A1 | SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF | RATIOPHARM GMBH (DE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142966-A1 | SALTS OF RASAGILINE AND PHARMACEUTICAL PREPARATIONS THEREOF | RAB35, RAB27A, RAB5B | MAOB 357/4885MAOA 257/4885ACHE 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.